CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (60)
2024
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208
-
Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 84
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
2023
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Frontiers in Neurology, Vol. 14
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
PharmacoEconomics, Vol. 40, Núm. 3, pp. 323-339
-
Consensus on early detection of disease progression in patients with multiple sclerosis
Frontiers in Neurology, Vol. 13
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180
Computer methods and programs in biomedicine
2021
-
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Computer Methods and Programs in Biomedicine, Vol. 208
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
-
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study
PLoS ONE, Vol. 15, Núm. 4
2019
-
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243
-
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)
Multiple Sclerosis and Related Disorders, Vol. 29, pp. 7-14
2018
-
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Multiple Sclerosis Journal, Vol. 24, Núm. 5, pp. 642-652